On September 18, Changchun High-tech Industry (Group) Co., Ltd. announced that its controlling subsidiary Changchun GeneScience Pharmaceuticals Co., Ltd. has reached a product cooperation agreement with Danish company ALK-Abelló A/S for allergen-specific immunotherapy (AIT). The companies will jointly develop and commercialize ALK's house dust mite (HDM) allergen-specific immunotherapy products in China, with GeneScience obtaining exclusive agency rights for three ALK-developed products within mainland China (the "cooperation territory"). The cooperation period extends until December 31, 2039.

According to the announcement, this cooperation involves three products, including two allergen-specific immunotherapy products and one skin prick test kit for mite allergen detection:

House Dust Mite Allergen Preparation (Antoda): A subcutaneous injection immunotherapy product for house dust mite allergens that is already marketed and sold in China.

Dust Mite Allergen Sublingual Tablet (ACARIZAX): The world's first sublingual immunotherapy tablet approved for allergic asthma and allergic rhinitis, which has received marketing approval from regulatory authorities in Europe, the United States, Russia, Australia, Japan, Singapore, South Korea, Hong Kong, Taiwan, and other countries and regions. It is currently being used in China's Greater Bay Area and Hainan Boao Lecheng Medical Pioneer Zone, while simultaneously conducting Phase 3 bridging registration studies in China.

Mite Allergen Skin Prick Test Kit (Anci): A skin prick test kit for mite allergen detection that is already marketed in China.

According to the cooperation agreement between both parties, the payment terms are as follows:

GeneScience will pay an initial payment of 32.7 million euros to obtain commercialization rights for the three products in mainland China. Based on the clinical trial regulatory approval progress of the dust mite allergen sublingual tablet (ACARIZAX) for adult, adolescent, and pediatric indications by Chinese regional drug regulatory authorities, GeneScience will subsequently pay registration milestone payments of 40 million euros.

GeneScience will bear the majority of future Phase 3 bridging clinical research and registration costs for adult and adolescent indications, while both parties will each bear 50% of the clinical research and registration costs for pediatric indications.

In the future, based on the sales performance of these products in the Chinese market, GeneScience may subsequently pay sales milestones of 105 million euros. GeneScience will bear the market promotion and sales-related costs for these products, while ALK will be responsible for production and supply of the products.